Work

From discordance to clinical decision support: integrating longitudinal imaging and ctDNA through multimodal artificial intelligence in precision oncology

Year: 2026

Type: article

Abstract: Accurate treatment-response assessment increasingly requires information that is spatial, molecular, and longitudinal. Imaging depicts lesion burden, anatomical distribution, and morphological evolution, whereas circulating tumor DNA (ctDNA) provides a systemic molecular signal shaped by tumor shedding, clonal composition, assay characteristics, and treatment pressure. Because these modalities measure non-identical dimensions, disagreement between them is clinically plausible and can reflect lead-lag kinetics, site-specific progression, clonal evolution, or technical uncertainty. In this focused narrative review, we synthesize evidence for imaging-ctDNA integration and propose a multidimensional, multilabel taxonomy of discordance spanning directional, temporal, spatial, molecular, and technical dimensions. We distinguish isolated from persistent discordance and emphasize exact temporal alignment, analytical confidence, and orthogonal confirmation. Current evidence supports prognostic complementarity and demonstrates measurable discordance across tumor types, but clinical actionability is context dependent. Randomized studies such as PADA-1 show that molecular-first treatment adaptation can be beneficial when a defined biomarker is linked to a validated intervention, whereas other trials illustrate that molecular detectability alone does not guarantee benefit from early treatment. We therefore frame multimodal artificial intelligence (AI) as an uncertainty-aware decision-support approach rather than an automated treatment selector. Future systems should preserve modality-specific information, handle irregular longitudinal sampling, quantify uncertainty, identify information gaps, and recommend evidence-matched reassessment. Prospective validation should prioritize clinical utility, harms, transportability, governance, and net benefit rather than discrimination alone.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2026.1963645

Authors: Jian Zheng, Luyang Chi, Yong Guo

Institutions: Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of TCM

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801